Can This Artificial Pancreas Cure Type-1 Diabetes?

Beta O2 has developed an implantable device, the Better Air Device, which may offer a cure for type 1 diabetes by using real living cells to produce insulin. Unlike a pancreas transplant, it doesn't require immunosuppressants due to engineered protective mechanisms. The device is implanted in the abdomen and requires daily oxygen injections, a minor procedure compared to daily insulin injections. Currently in phase one trials in Sweden, Beta O2 aims to launch in Europe by 2017-2018 and later in the US. The company has raised $21 million but plans further fundraising to expedite market entry. The device targets a multi-billion dollar market with 17 million type 1 diabetics worldwide.

What is the expected timeline for the Beta O2 device to hit the market?

What is the estimated market size for the Beta O2 device?